Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ElsaLys Biotech
Lyon, Auvergne-Rhone-Alpes, Franceelsalysbiotech.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
Inolimomab is being administered in France before marketing authorization in Europe for acute cortico-resistant or corticosteroid-dependent graft-versus-host disease. Around 30 patients in France were treated with inolimomab during its first year under compassionate use authorization (cATU) despite the pandemic[3].
- Therapeutic areas
- HematologyImmunology
- Modalities
- Therapeutic antibodiesMonoclonal antibodiesImmunotherapy
- Industry
- Biotech
02
Partnerships
EFSCurie InstituteTumor Institute of TurinSATT-Sud Est
Beyond the preview
Go deeper on ElsaLys Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ElsaLys Biotech.